As a precautionary measure, Pfizer appealed to the Lazio Regional Administrative Court regarding the guidelines of the regulation of scientific drug information, ratified by the Conference of Presidents of the Regions. The company declares itself in favor of the regulation of medical-scientific information, but believes that some aspects of the current regulations could facilitate the activity of some pharmaceutical companies to the detriment of others. The company is above all against article 4, which indicates a maximum number of visits per doctor by each whistleblower of a given company. The same limit applies for 'the same product containing the same active ingredient'. Pfizer believes that this way companies promoting the same product under different brand names keep a high degree of information about the same drug to the same doctor.
From the Only 24 Hours.
